Treatment of hypertension in dialysis and essential hypertension patients with nifedipine. 1982

H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross

The immediate antihypertensive effect of 10 mg nifedipine sublingually (nifedipine test), was measured in 19 chronic renal failure hypertensive patients on dialysis and 34 essential hypertensive patients with normal kidney function. The blood pressure decreased significantly in both groups. The minimal values were observed between 30 and 60 minutes after the sublingual administration of nifedipine. The blood pressure decreased from 178 +/- 3.3/104.0 +/- 3.9 to 136.0 +/- 4.7/87.5 +/- 5.1 mm Hg (p less than 0.001) in dialysis patients and from 176.8 +/- 4.5/107.1 +/- 2.4 to 133.0 +/- 3.0/81.7 +/- 2.2 mm Hg in essential hypertension patients (p less than 0.001). The decrease in blood pressure during the test had a significant positive correlation with the pre-test values. Thirteen hypertensive patients on dialysis and 20 essential hypertensive patients completed 2 weeks of daily oral nifedipine therapy, with a dose of 30 to 40 mg per day. The mean blood pressure at the end of the 2 weeks of treatment decreased from 179.5 +/- 4.5/108.5 +/- 5.3 mm Hg to 154.4 +/- 6.3/82.3 +/- 2.6 mm Hg (p less than 0.001) in dialysis patients, and from 176.8 +/- 5.8/110.3 +/- 2.9 to 151.3 +/- 5.3/93.5 +/- 2.6 mm Hg (p less than 0.001) in essential hypertension patients. The present results reveal that nifedipine has a powerful immediate as well as a long-term antihypertensive action in dialysis patients with high blood pressure. This effect is similar to that obtained in essential hypertensive patients.

UI MeSH Term Description Entries
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
June 1989, Cardiovascular drugs and therapy,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
September 1985, Journal of clinical pharmacology,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
January 1982, Revista espanola de cardiologia,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
January 1982, European journal of clinical pharmacology,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
January 1982, Journal of cardiovascular pharmacology,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
May 1985, Revista medica de Chile,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
January 1991, Proceedings of the Western Pharmacology Society,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
October 1988, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
December 1992, Arzneimittel-Forschung,
H E Eliahou, and A Iaina, and R Schneider, and D Cohen, and D Goldfarb, and M Gross
November 1991, The American journal of cardiology,
Copied contents to your clipboard!